Unmet Needs for Patients With AML
Naval G. Daver, MD, discusses the unmet needs that still exist in the treatment of acute myeloid leukemia.
Transplants in the AML Treatment Landscape
Naval G. Daver, MD, discusses how stem cell transplants factor into the current treatment landscape of acute myeloid leukemia.
Shifts the the AML Treatment Landscape
Naval Daver, MD, discusses the evolution in the treatment of acute myeloid leukemia for both older and younger patient populations.
Magrolimab Shows Promise in MDS and AML
Naval G. Daver, MD, discusses the latest research on magrolimab, a CD47 monoclonal antibody, for patients with acute myeloid leukemia and myelodysplastic syndrome.
Exploring the Data for AML Treated With Magrolimab and Azacitidine
Naval G. Daver, MD, discusses a phase 1b trial evaluating the efficacy of margolimab and azacitidine combination for patients with acute myeloid leukemia.
Second-Generation FLT3 Inhibitors Produce Higher Response Rates in AML
Naval G. Daver, MD, discusses how the efficacy compares between first- and second-generation FLT3 inhibitors in acute myeloid leukemia.
Combination Checkpoint Therapy Gains Ground in AML and MDS
Checkpoint-based immune therapies have revolutionized the therapy of solid tumors by achieving breakthrough improvements in melanoma, lung cancer, renal cancer, bladder cancers, and head and neck tumors, among others.
2 Commerce Drive Cranbury, NJ 08512